Healthcare / BiotechnologyNasdaqGS
$10.14
-0.36 (-3.47%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-251.0M · quality 55.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
54/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.7B
P/E
3.9x
↓EV/EBITDA
3.6x
↓ROE
-344.7%
↓Gross Margin
93.5%
↑Debt/Equity
-1.95
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-22.3%
FCF / Net income
-0.57x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.12B · net income $440.3M · FCF $-251.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $1.12B | $1.12B | $682.2M | $556.4M | $1.60B | $1.15B | $475.6M | $18.7M | $34.3M | $31.2M | $15.4M | $36.3M | $30.7M | $20.9M | $22.1M | $14.7M | $343000.00 | — |
| Net Income | $440.3M | $440.3M | $-187.5M | $-545.1M | $-657.9M | $-1.74B | $-418.3M | $-132.7M | $-184.7M | $-183.8M | $-280.0M | $-156.9M | $-82.9M | $-52.0M | $-28.5M | $-19.4M | $-35.7M | $-40.3M |
| EBITDA | $492.3M | $492.3M | $-108.0M | $-487.4M | $-604.7M | $-1.67B | $-412.4M | $-115.5M | $-166.5M | $-164.1M | $-261.4M | $-152.1M | $-79.3M | $-49.8M | $-28.0M | $-20.0M | $-37.1M | $-36.2M |
| EPS | 2.58 | 2.58 | -1.23 | -5.41 | -8.42 | -23.44 | -7.27 | -5.51 | — | — | — | — | — | — | — | — | — | — |
| Gross Margin | 93.5% | 93.5% | 70.3% | 38.2% | 43.5% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | 49.0% | 49.0% | -36.5% | -101.8% | -40.3% | -147.1% | -87.6% | -646.1% | -507.2% | -550.8% | -1752.8% | -433.8% | -273.0% | -250.7% | -134.4% | -146.9% | -11222.7% | — |
| Net Margin | 39.2% | 39.2% | -27.5% | -98.0% | -41.1% | -152.1% | -87.9% | -711.0% | -538.8% | -589.5% | -1823.5% | -432.9% | -270.5% | -248.5% | -129.1% | -131.8% | -10410.5% | — |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | -1.95 | -1.95 | -0.37 | -0.32 | -0.87 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 2.48 | 2.48 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $-251.0M | $-251.0M | $-101.9M | $-772.8M | $-508.9M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Returns | ||||||||||||||||||
| ROE | -344.7% | -344.7% | 30.1% | 76.0% | 103.8% | 495.8% | -66.7% | 71.3% | 110.0% | 180.6% | 5048.1% | -53.6% | -36.1% | -25.6% | -35.5% | -36.0% | -60.5% | -57.7% |
| Valuation | ||||||||||||||||||
| P/E | 3.93 | 3.93 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 3.58 | 3.58 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | 64.7% | 64.7% | 22.6% | -65.2% | — | 141.0% | 2448.5% | -45.6% | 10.0% | 103.1% | -57.6% | 18.2% | 46.6% | -5.3% | 50.3% | 4182.2% | — | — |
| EPS Growth | 309.8% | 309.8% | 77.3% | 35.7% | — | -222.4% | -31.9% | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-29.6%
EPS terminal req.
$0.90
Spread vs growth
339.4%
5Y implied EPS CAGR
-15.8%
EPS terminal req.
$1.09
Spread vs growth
325.6%
10Y implied EPS CAGR
-3.8%
EPS terminal req.
$1.75
Spread vs growth
313.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+43.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.23 → 2.58
Residual
+43.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.